November 9, 2009
Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacture and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Third Annual Canaccord Cardiovascular Conference on Tuesday, November 10. (Read more...)

November 5, 2009
Volcano Reports 22 Percent Increase in Third Quarter Revenues
Volcano Corporation (Nasdaq: VOLC) today reported revenues of $53.9 million for the third quarter of fiscal 2009. The results for the quarter ended September 30, 2009, represent an increase of 22 percent over revenues of $44.1 million in the third quarter of 2008. (Read more...)

September 24, 2009
Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcano's VH® IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks
PROSPECT results presented today include the landmark finding that angiographically mild lesions with certain morphologic features on grayscale and VH IVUS present with a 3 year cardiac event rate of 17%, versus other morphologies (indistinguishable by conventional angiograms) with three year event risks of less than 1%. (Read more...)

September 23, 2009
Volcano Corporation Praises FAME Study Results
The results of the prospective, multi-center trial at 12-months, originally published in the New England Journal of Medicine in 2009, demonstrate that patients with multi-vessel coronary artery disease who were treated by FFR guidance had a 34% reduction in death and myocardial infarction (MI) compared to angiographic guidance alone. The clinical benefit of FFR-guidance at two years showed the sustained reduction in death and heart attacks of 34%. (Read more...)

September 10, 2009
Volcano Corp. Announces Events at TCT Meeting
Volcano Corporation (Nasdaq: VOLC), a leader in the fields of Intravascular Ultrasound (IVUS) and Functional Measurement (FM) today announced a wide variety of events taking place at this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco. A wide spectrum of activities will demonstrate how these technologies can improve the results obtained from angioplasty and stenting, and includes late-breaking clinical trials, symposia with panels of experts, live case demonstrations and an investor event. (Read more...)

September 1, 2009
Volcano Corporation Presentation at Weisel Conference to be Webcast
Volcano Corporation said today that it will be participating in the Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9. The presentation by John Dahldorf, chief financial officer, will begin at 8 a.m., Eastern Daylight Time (5 a.m., Pacific Daylight Time). (Read more...)

August 25, 2009
Volcano Corporation and Siemens Healthcare Announce Global Resale Agreement for Volcano IVUS/FFR Systems
Volcano Corporation (Nadsaq: VOLC), announced today that it has entered into a non-exclusive, global resale agreement with Siemens Healthcare, a sector of Siemens AG (NYSE: SI). Under this agreement, Siemens will resell Volcano-branded s5i IVUS/FFR systems and accessories alongside Siemens' Artis family of X-ray systems. (Read more...)

August 7, 2009
Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast
Volcano Corporation (Nadsaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Canaccord Adams 29th Annual Global Growth Conference on Thursday, August 13. (Read more...)

August 4, 2009
Volcano Reports 30 Percent Increase in Second Quarter Revenues
Volcano's CEO Scott Huennekens states, "IVUS disposable revenues in the quarter were $31.8 million, a record quarter for this business, and a 26 percent increase over the second quarter a year ago. FM revenues in the quarter were a record $7.2 million, with FM disposable revenues increasing 75 percent over the second quarter a year ago. In addition, we continued our successful IVUS/FM console placement initiatives, placing 233 consoles versus 178 a year ago, an increase of 31 percent.... These results portray the value of our technology innovation, effective sales and marketing programs and the growing recognition among clinicians that IVUS and FM can play an important role in the diagnosis and treatment of patients. (Read more...)

July 27, 2009
Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC) will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), Tuesday, August 4, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

July 8, 2009
Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman
Volcano Corporation said today it has signed a termination agreement with its largest distributor in Japan, Goodman Company, Ltd. This agreement, which took effect today, will enable Volcano to accelerate its transition to a direct sales force in the market to support its intravascular ultrasound (IVUS) and Functional Measurement (FM) consoles and disposables, as well as products currently in development. (Read more...)

July 5, 2009
Interview with Giulio Guagliumi, MD About Optical Coherence Tomography and Stents
Dr. Giulio Guagliumi, an internationally recognized leader in the use of Optical Coherence Tomography (OCT) in the coronary arteries, practices in the Cardiovascular Department of Ospedali Riuniti di Bergamo in Bergamo, Italy. Dr. Guagliumi has been published in numerous peer-reviewed journals and is principal investigator in several clinical trials assessing the performance of stents inside the coronary artery, using OCT imaging. In this interview, he discusses the dynamic changes occurring with this technology. (Read more...)

May 25, 2009
Meeting to Highlight Use of New Imaging Technologies for Guiding Stent and Angioplasty Procedures
This week marks one of the first courses to focus exclusively on the range of innovative intravascular imaging and measurement technologies that have been gaining in use over the past couple of years. "OCT, IVUS, FFR: When, Where, How" will be held on May 28 and 29 in Bergamo, Italy. The course will utilize the newest innovations in Optical Coherence Tomography(OCT), Intravascular Ultrasound (IVUS), Virtual Histology (VH) and Fractional Flow Reserve (FFR) and how they can be used to optimize percutaneous procedures, such as angioplasty and stenting. (Read more...)

May 19, 2009
Optical Coherence Tomography (OCT) Presentations by Volcano at EuroPCR 2009
Volcano Corporation (Nasdaq: VOLC) today highlights its technology leadership position in the emerging field of Optical Coherence Tomography (OCT) at the EuroPCR conference in Barcelona, Spain. Volcano's wholly owned subsidiary, Axsun, has developed what we believe to be a truly revolutionary new class of ultra-miniaturized external cavity lasers that are expected to power the highest performance OCT systems for intracoronary and other medical imaging segments. (Read more...)

May 19, 2009
New Intravascular Ultrasound (IVUS) Study of Underexpanded Stents, Thrombosis and Restenosis
A study, published in the current issue of JACC Interventions, details 120 drug-eluting stent cases as viewed by intravascular ultrasound (IVUS) in order to examine characteristics that may lead to in-stent restenosis (ISR) or stent thrombosis. The researchers found that in cases of thrombosis, the proximal parts of many of the stents were inadequately expanded. An accompanying editorial suggests greater use of IVUS and more attention to detail can reduce the number of these adverse clinical events. (Read more...)

May 18, 2009
Volcano Announces Worldwide Exclusive Distribution Agreement With Lumen Biomedical for Xtract™ Thrombus Aspiration Catheter
Volcano Corporation (Nasdaq: VOLC) today announced an exclusive worldwide distribution agreement to initiate the formal launch of the Xtract™ thrombus aspiration catheter, manufactured by Lumen Biomedical. The Xtract thrombus aspiration catheter is available for immediate sale in the U.S. and Europe. This marks Volcano's entry into what some believe is a $70+ million aspiration market. (Read more...)

May 13, 2009
Volcano Corporation Presentation at JMP Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Eighth Annual JMP Securities Research Conference on Monday, May 18. The presentation by John Dahldorf, chief financial officer, will begin at 3:00 p.m., Pacific Daylight Time (6:00 p.m., Eastern Daylight Time). (Read more...)

May 6, 2009
Volcano Corporation Presentation at Bank of America/Merrill Lynch Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Bank of America and Merrill Lynch 2009 Health Care Conference on Thursday, May 14. The presentation by Scott Huennekens, president and chief executive officer, will begin at 11:20 a.m., Eastern Daylight Time (8:20 a.m., Pacific Daylight Time). (Read more...)

May 5, 2009
Volcano Reports 1st Quarter Revenues of $49 Million; IVUS and FM Businesses Grew 24%
Volcano Corp. (VOLC) reports a greater loss over the same period in 2008, due mainly to lower margins and the strength of the dollar. However, revenue of intravascular ultrasound and functional measurement products grew 24%. (Read more...)

May 4, 2009
Effectiveness in Stenting
As Volcano's CEO Scott Huennekens writes in an op-ed piece, there's a whole toolbox of devices and techniques that are candidates for "comparative effectiveness" in that they may be able to increase the success of interventional procedures -- or even target patients who need these procedures more accurately. (Read more...)

April 27, 2009
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report its operating results for the first quarter of fiscal 2009 on Tuesday, May 5. (Read more...)

March 27, 2009
Volcano Announces the Availability of Integrated Fractional Flow Reserve Technology on All Major Cardiovascular X-ray Angiography Systems
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced the availability of its integrated Fractional Flow Reserve (FFR) technology on all major cardiovascular x-ray systems: GE, Philips, Siemens and Toshiba. (Read more...)

March 27, 2009
Volcano Announces Schedule of Events at the ACC 2009, Integration into Indec and Medis Software Platforms
Joe Burnett, Vice President of Marketing at Volcano commented, "Three years ago, you could flip through the ACC program and see a couple of presentations on intravascular assessment using IVUS or FFR. This year, there are more than 50 presentations, case reviews and abstracts focused on FFR, IVUS, OCT, Forward-Looking IVUS, and VH® IVUS plaque composition. Word is getting out that more precise guidance during PCI is important, and the sheer number of talks focused on higher resolution tools, highlight the increased demand for access to these technologies. (Read more...)

March 26, 2009
ACC 2009 Sessions on Intravascular Imaging and Functional Measurement
The upcoming American College of Cardiology Annual Scientific Sessions, being held in Orlando, Florida from March 28-31 is featuring more than 50 presentations, case reviews and abstracts focused on intravascular imaging and functional measurement modalities, such as Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS, Optical Coherence Tomography (OCT), as well as newer technologies, like Forward-Looking IVUS and VH plaque composition. (Read more...)

February 20, 2009
Volcano Corporation Announces Webcast of February 25th Analyst Day
Volcano Corporation (Nasdaq: VOLC) will hold its 2009 Analyst Day on Wednesday, February 25, at the NASDAQ MarketSite in New York City. The webcast will begin at 10 a.m., Eastern Standard Time (7 a.m., Pacific Standard Time) and conclude at 2 p.m., Eastern Standard Time (11 a.m., Pacific Standard Time). (Read more...)

February 17, 2009
Volcano Reports Full Year Revenues Increase 31 Percent
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today reported that revenues for the full year 2008 increased 31 percent over full year 2007 and that revenues for the fourth quarter of 2008 increased 23 percent over revenues in the fourth quarter of 2007. (Read more...)

February 12, 2009
Volcano CEO to Present at Roth Capital Partners Conference; Webcast Announced
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Roth Capital Partners 21st Annual Growth Stock Conference on Wednesday, February 18. (Read more...)

February 6, 2009
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report is operating results for the fourth quarter and all of fiscal 2008 on Tuesday, February 17. (Read more...)

January 20, 2009
Volcano Highlights Commitment, Market Acceptance of FFR Product Line
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today commented on the increased demand for their FFR and IVUS capable consoles, as well as their FFR pressure guide wires. Since announcement of the FAME study results at the TCT in October, the FFR option for Volcano's s5i integrated imaging console was included in more than 90% of all new orders. (Read more...)

January 17, 2009
FAME: "Back to the Future"
The leading story about stents this past week has been the publication of the FAME study and how a new St. Jude Medical device that measures blood pressures inside the artery can reduce the number of unnecessary angioplasty and stent procedures. Well...it's not a new device; it's definitely not a new concept; and St. Jude doesn't exactly get the credit for it either, since their chief role was to acquire the company that created the product. But it is an important study! (Read more...)

January 15, 2009
Better Outcomes for Stents When Fractional Flow Reserve (FFR) is Used
One-third fewer stents were used in the FFR group and the difference in outcomes at one year were significant: the FFR group showed a 28% lower incidence of major adverse cardiac events (repeat procedure to open the artery, heart attack or death) -- 18.3% vs. 13.2%. The implication in these results is that placing stents in lesions that are not responsible for ischemia is not only not necessary, but may cause worse outcomes. (Read more...)

January 15, 2009
Interview with Nico H. J. Pijls, MD, PhD
Angioplasty.Org conducts an exclusive interview with Dr. Nico Pijls, co-principal investigator of the FAME study (Fractional Flow Reserve vs. Angiography for Multivessel Evaluation) published today in the New England Journal of Medicine. The study concludes that "Routine measurement of FFR in patients with multivessel coronary artery disease who are undergoing PCI with drug-eluting stents significantly reduces the rate of the composite end point of death, nonfatal myocardial infarction, and repeat revascularization at 1 year." (Read more...)

January 7, 2009
Volcano Announces Closing of Axsun Technologies Acquisition
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it has closed its previously announced acquisition of Axsun Technologies, Inc. (Read more...)

January 6, 2009
Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14. (Read more...)

December 23, 2008
Volcano Announces Acquisition of Axsun Technologies, Inc.
Volcano Corporation said today that it has entered into a definitive agreement to acquire Axsun Technologies, Inc., a privately-held company that is a leading developer and manufacturer of lasers and optical engines used in medical Optical Coherence Tomography (OCT) imaging systems and advanced photonic components and subsystems used in other industrial applications. (Read more...)

December 9, 2008
Interview with Szilard Voros, MD
Virtual Histology IVUS allows the cardiologist to see not only the plaque inside the artery, but what the composition of that plaque is. We discuss this new technology with one of the leading researchers in the field. (Read more...)

December 2, 2008
Volcano Corporation: Intravascular Imaging Ascending
In the midst of a recession, Volcano Corporation has shown a 19% increase in its stock value over the past six months. Its only competitor in the U.S. market suffered a 55% decrease. Why? (Read more...)

November 24, 2008
Volcano Corporation Presentation at Piper Jaffray Conference to Be Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the 20th Annual Piper Jaffray Health Care Conference on Tuesday, December 2. (Read more...)

November 5, 2008
78% Increase in Intravascular Ultrasound Systems Sales Boosts Volcano Quarterly Growth by 40%
For the quarter ended September 30, 2008, Volcano reported revenues of $44.1 million versus revenues of $31.5 million in the same period a year ago. The company said that its financial performance was driven by a 78 percent increase in intravascular ultrasound (IVUS) system revenues and a 29 percent increase in IVUS disposable revenues year-over-year. (Read more...)

November 5, 2008
Volcano Corporation To Report Third Quarter Results Today During Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC) will report its operating results for the third quarter and first nine months of fiscal 2008 on Wednesday, November 5. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time (5 p.m. Eastern Standard Time). (Read more...)

October 22, 2008
ODESSA Trial Looks Inside Drug-Eluting Stents With Optical Coherence Tomography (OCT)
(Updated) The results of ODESSA showed that OCT could indeed accurately measure strut coverage and NIH. An interesting data point was confirmation of the differences in the currently available DES. ODESSA looked at Cypher, Taxus, Endeavor and Bare Metal stents. The results showed that at six months, virtually all the struts of the Endeavor stent were covered -- the healing was even more complete than with bare metal stents, which reinforces reports of little or no very late stent thrombosis with the Endeavor. At the same time, an inverse relationship was observed between strut coverage and growth of neo-intimal hyperplasia (NIH) -- the Endeavor had the highest NIH growth of the DES (also called Late Loss) while the Cypher stent had the least Late Loss, but the highest number of uncovered struts. (Read more...)

October 15, 2008
Volcano Corporation Announces Launch of PrimeWire™ Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
Volcano Corporation (Nasdaq: VOLC) today announced the launch of the PrimeWire™ Pressure Guidewire, and the s5-FFR Option for its existing installed base of s5 and s5i imaging consoles in the U.S. The PrimeWire is Volcano's newest pressure guidewire, capable of measuring pressure gradients across a lesion to determine the ischemic nature of the stenosis, and can also help determine the extent to which the blockage is flow-limiting. (Read more...)

October 13, 2008
Volcano Corporation Announces Schedule of Events for TCT (Transcatheter Cardiovascular Therapeutics Conference) 2008
The company has announced a wide range of events including live case transmissions, symposia to highlight new products and the clinical utility of Volcano technologies including FFR, IVUS, VH IVUS, OCT and Forward-Looking IVUS (Read more...)

October 6, 2008
Volcano Corporation Relocating Corporate Headquarters to San Diego
The new corporate headquarters is located in the Carmel Valley area of San Diego and now houses corporate executives, marketing, finance, accounting, corporate human resources, legal and catheter engineering. The company intends to expand its operations in San Diego in the future. The company's core research and development, manufacturing, operations, quality and local human resources functions will remain in Volcano's facilities in Rancho Cordova, CA. (Read more...)

September 20, 2008
Volcano Corporation Schedules Events for 2008 TCT Transcatheter Cardiovascular Therapeutics Meeting
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer of intravascular ultrasound (IVUS) and functional measurement (FM) technology, has scheduled several events to be held during the 2008 TCT meeting in Washington DC, being held October 12-17, 2008 at the Washington Convention Center. (Read more...)

September 15, 2008
Volcano Announces Resignation of Olav Bergheim from Board of Directors
The Company announced today that Olav B. Bergheim, the Volcano's chairman of the board, will resign from the board of directors effective as of the close of business on January 1, 2009. A co-founder of Volcano, Bergheim is the managing director of Fjord Ventures LLC, a venture capital firm he founded, and has served as chairman of Volcano's board since 2001. (Read more...)

September 2, 2008
Volcano's Virtual Histology Imaging Allows Major Drug Study (IBIS-2) to Measure "Vulnerable Plaque"
Volcano's VH® IVUS technology is being used in an imaging study of GlaxoSmithKline's novel investigational compound, Darapladib. Dubbed the IBIS-2 (Integrated Biomarker and Imaging Study) the study results demonstrate the benefits of VH® IVUS in drug development. (Read more...)

July 29, 2008
Volcano Corporation Schedules Second Quarter Conference Call and Webcast
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the second quarter and first six months of fiscal 2008 on Tuesday, August 5. (Read more...)

July 8, 2008
Intravascular Ultrasound (IVUS) May Reduce Drug-Eluting Stent Thrombosis by a Third
A provocative study in the current issue of the European Heart Journal concludes that: "IVUS guidance during DES implantation has the potential to influence treatment strategy and reduce both DES thrombosis and the need for repeat revascularization." The results were striking, surprising even the investigators. At 12 months, definite stent thrombosis had occurred in 0.7% of the patients in whom intravascular ultrasound guidance had been utilized, but in patients where IVUS was not used, the stent thrombosis rate was 2.0%, almost three times higher. (Read more...)

June 28, 2008
Interview with Ron Waksman, MD, FACC
Our IVUS Center features a discussion about an important new study, just published in the European Heart Journal, showing that IVUS guidance can improve outcomes with drug-eluting stents, including significantly lower rates of stent thrombosis. (Read more...)

June 3, 2008
When Can I Stop Taking Plavix? -- A New Imaging Modality May Help Patients and Physicians Determine Optimal Duration of Antiplatelet Therapy in the Not-Too-Distant Future
(Updated) The question on the minds of a great many patients who have had a drug-eluting stent implanted is: "When can I stop taking Plavix? When will my drug-eluting stent be completely healed?" It's THE question of the day, and no one is really sure of the answer. However, a new imaging technology, called Optical Coherence Tomography or OCT, may help with this issue in the not-too-distant future.. (Read more...)

May 19, 2008
Volcano Corporation Presentation at JMP Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a provider of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Seventh Annual JMP Securities Research Conference on Tuesday, May 20. (Read more...)

May 19, 2008
Volcano Announces Acquisition of Novelis, Inc.
Novelis' Forward-Looking IVUS technology platform is expected to enable Volcano to offer an expanded line of minimally invasive diagnostic and therapeutic devices, especially in the area of chronic total occlusions (CTO). (Read more...)

May 15, 2008
Intravascular Ultrasound (IVUS) Use Growing with Integration into Routine Cath Lab Imaging
Intravascular Ultrasound, or IVUS, is an imaging technology that looks at arteries from the inside out. Invented two decades ago, IVUS recently has been gaining in usage due to safety concerns about stent thrombosis and proper stent placement during angioplasty. (Read more...)

May 12, 2008
Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System; Presence at the EuroPCR08 will highlight choice of different modalities available on single integrated imaging platform
Scott Huennekens, President and Chief Executive Officer of Volcano, commented, "Reaching this milestone as quickly as we have is a clear indication of the clinical adoption of IVUS and FFR, and the competitiveness of our product. More and more physicians are using intravascular imaging to measure lesion significance and improve PCI technique. The ease of use and flexibility of our newest systems have been very well received. These new systems are gaining traction with both new IVUS users, as well as those who are looking to replace their legacy IVUS technology." (Read more...)

May 8, 2008
Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
Volcano Corporation (Nasdaq: VOLC) announced today the first human procedure using the Volcano OCT Imaging catheter. The procedure was performed by Dr. Patrick Serruys at the Thoraxcenter, in Rotterdam, Netherlands. Volcano OCT will complement its existing line of IVUS imaging catheters and pressure guidewires used for coronary imaging and lesion assessment. (Read more...)

May 7, 2008
Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the first quarter of fiscal 2008. (Read more...)

May 5, 2008
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
SATURN is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres This study by AstraZeneca is designed to measure the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease. (Read more...)

April 29, 2008
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement(FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the first quarter of fiscal 2008 on Wednesday, May 7. (Read more...)

March 31, 2008
Volcano Corporation Announces North America Resale Agreement with Royal Philips Electronics
Volcano Corporation, leading manufacturer of intravascular ultrasound (IVUS), announced today that it has entered into a non-exclusive, resale agreement covering North America with Royal Philips Electronics. Under this agreement, Philips will resell Volcano-branded s5i IVUS systems and accessories alongside of the Philips Allura Xper FD X-ray systems. (Read more...)

March 28, 2008
Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
Volcano Corporation, a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today the U.S. and European launch of the s5-Revo and s5-FFR (fractional flow reserve) options for the s5i integrated Imaging platform. (Read more...)

March 27, 2008
Intravascular Ultrasound (IVUS) Events at American College of Cardiology Annual Meeting
Intravascular ultrasound (IVUS) is scheduled to be part of 29 separate sessions at this weekend's annual meeting of cardiologists in Chicago. In addition, IVUS will be used by interventionalists who will be performing 14 live procedures, to be broadcast to the Convention Center at McCormick Place from Lenox Hill Hospital in New York, and other medical centers in California, London, Germany, Japan and Australia. (Read more...)

March 12, 2008
Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, will be participating in the Cowen and Company 28th Annual Health Care Conference on Monday, March 17. The presentation by president and CEO, Scott Huennekens, will begin at 3:15 p.m., Eastern Daylight Time (12:15 Pacific Daylight Time). (Read more...)

February 12, 2008
Volcano Reports 35% Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46%
"This growth in our IVUS business occurred despite a sluggish global PCI market. We believe the ease of use and integration provided by our s5 family of consoles, along with a growing volume of data demonstrating the value of IVUS in stenting procedures, is driving our increased market presence in the IVUS arena," he added. "We are encouraged by what appear to be recent favorable trends in stenting procedures and believe this will further the growth of our IVUS offerings," he continued. (Read more...)

February 7, 2008
Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
These two new product offerings now enable rotational IVUS and FFR to operate on the same integrated Volcano s5 Imaging System as Volcano's previous line of phased array IVUS catheters and functionality. For the first time, physicians can choose among three powerful diagnostic tools -- all on the same integrated IVUS platform. (Read more...)

December 10, 2007
Volcano Announces Agreement to Acquire CardioSpectra
Volcano Corporatio, a provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart disease, said today that it has reached a definitive agreement to acquire CardioSpectra, Inc., a privately-held company developing innovative Optical Coherence Tomography (OCT) technology. CardioSpectra's unique OCT imaging system is expected to complement Volcano's existing product offerings and will further enhance Volcano's position as an imaging technology leader in the field of interventional medicine. (Read more...)

November 8, 2007
Volcano Reports Record Third Quarter Revenues
Volcano Corporation, a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products, today reported record revenues of $31.5 million, a 13 percent increase over revenues of $27.8 million in the third quarter a year ago. (Read more...)

November 8, 2007
Cordis Europe Partnering With Volcano Europe to Provide Access to Intravascular Imaging (IVUS) for Use in Drug-Eluting Stent Procedures
One of the major drug-eluting stent makers seems to agree with the idea that intravascular ultrasound (IVUS) guidance is critical for the proper placement of their devices. This move is a significant one for Volcano, which has long been trying to educate the interventional cardiology community about IVUS. (Read more...)

October 22, 2007
Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
Volcano Corporation, a leading manufacturer of intravascular ultrasound (IVUS) and functional measurement (FM) technology, announced today activities planned for the 2007 Transcatheter Cardiovascular Therapeutics (TCT) conference that will take place from October 20th to October 25th in Washington D.C. (Read more...)

October 22, 2007
Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
3,000 patients will be studied as part of a multi-center IVUS sub-study, part of the Cardiovascular Research Foundation's ADAPT-DES Study to quantify the causes and cures of thrombosis in drug-eluting stents. (Read more...)

September 4, 2007
Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
Volcano Corporation, a provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart diseases, said today that it will be participating in the Bear Stearns 2007 Healthcare Conference on Tuesday, September 11. (Read more...)

July 24, 2007
Volcano Corporation Announces Japan Approval of the s5i Integrated IVUS Platform
Volcano Corporation today announced approval of the s5i Integrated IVUS System by necessary regulatory authorities in Japan, granting entry into the Japanese market. Volcano expects to launch the s5i into Japan, which represents the largest Intravascular Ultrasound (IVUS) market worldwide, during the current quarter. (Read more...)

May 30, 2007
Most Heart Stents Are Placed Imperfectly, Increasing Risk of Heart Attack or Reclosure
Results of a new study show that stent placement involves a "geographic miss" two-thirds of the time, resulting in a three-fold increased risk of heart attack and a two-fold increase in reintervention. The article includes interviews with Dr. Marco Costa of the University of Florida College of Medicine in Jacksonville, chief investigator for the S.T.L.L.R. study, and Dr. Antonio Colombo of Columbus and San Raffaele Hospitals in Milan, Italy (Read more...)

May 7, 2007
Volcano Corporation Reports 49 Percent Increase in Revenues; IVUS Disposable Sales Increase 33 Percent
(source: Volcano Corporation)
Volcano Corporation, a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart diseases, today reported that revenues in the first quarter of 2007 increased 49 percent over revenues in the first quarter a year ago. (Read more...)

April 25, 2007
Volcano Corporation Schedules First Quarter Conference Call, Webcast
(source: Volcano Corporation)
The company will hold a conference call to discuss its financial results and operating activities to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m. Eastern Daylight Time), Monday, May 7, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

April 18, 2007
COURAGE, SPIRIT Data May Support Role of Advanced Imaging and Diagnosis With IVUS and FFR
(source: Volcano Corporation)
The results of recent studies presented at this year's American College of Cardiology may support the role played by intravascular ultrasound (IVUS) and fraction flow reserve (FFR) in diagnosing the need for stenting more accurately than standard angiography and, when the use of a stent is indicated, aiding in the accuracy of stent placement. (Read more...)

April 4, 2007
Volcano Corp. Reports Use of Intravascular Ultrasound (IVUS) Increasing as Physicians Refocus on Stent Technique
While use in the United States of DES has decreased from 89% to an estimated 70% over the past year, driven by concerns over stent thrombosis causing heart attacks, and confidence in Bare Metal Stent (BMS) safety, for the same period, Volcano has seen an increase of 25% in IVUS revenue, demonstrating more reliance on detailed imaging to guide optimal DES and BMS placement. (Read more...)

April 3, 2007
Volcano Corporation and ev3 Inc. Announce Joint Marketing and Distribution Agreement
Under the terms of the agreement, Volcano will have the opportunity to sell ev3's SpiderFX Embolic Protection Device in conjunction with their Intravascular Ultrasound (IVUS) and Functional Measurement (FM) devices for use in saphenous vein grafts (SVG's) in the U.S. (Read more...)

February 13, 2007
Volcano Corporation and Cordis Endovascular Japan Announces Distribution Agreement for IVUS Indications
(source: Volcano Corporation)
Volcano Corporation today announced the signing of a distribution agreement with Johnson & Johnson K.K., Medical Company.The agreement appoints Cordis Endovascular Systems Japan as a distributor of IVUS products for use in peripheral and endovascular procedures in Japan.

November 27, 2006
Intravascular Ultrasound (IVUS) Imaging Technology May Help Lower Rates of Late Stent Thrombosis
While there are a number of causes of late stent thrombosis that have been identified, one of the factors most associated is poor apposition (incomplete expansion or suboptimal positioning) of the drug-eluting stent. A recent presentation by Dr. William Wijns of Aalst, Belgium at last month's TCT meeting showed that in 77% of the late stent thrombosis cases (clotting one year after implantation) the stent showed incomplete apposition (mal-apposition was seen in only 12% of cases where there was no stent thrombosis). (Read more...)

November 13, 2006
Volcano Announces Clinical Review of Key Presentations From TCT 2006
(source: Volcano Corporation)
The whole field of intravascular ultrasound (IVUS) is gaining in importance as problems are surfacing about drug-eluting stents. The value of IVUS

October 20, 2006
Volcano Corporation and MediGuide Ltd. Announce Collaboration for Advanced Imaging and Navigation Technology
(source: Volcano Corporation)
The companies initially plan to develop Guided IVUS (GIVUS), a product which will integrate MediGuide's Medical Positioning System (MPS) with Volcano's intravascular ultrasound (IVUS) system. This combination of technologies will expand the two dimensional aspect of the existing IVUS image into a three dimensional image that is designed to provide more useful clinical information, allow for easier interpretation of the image by interventional cardiologists and improve the clinical utility of the image.

October 11, 2006
Volcano Announces First Permanent Installations of the Integrated s5i IVUS Imaging System
(source: Volcano Corporation)
The company today announced the first permanent installations of the s5i IVUS (intravascular ultrasound) imaging system in both the U.S. and Europe. The s5i is Volcano's first IVUS system that can be integrated into any new or existing cath lab configuration. Through a series of customizable components, Volcano can now tailor an integrated IVUS solution to the unique user and workflow needs for any vendor's cath lab type or configuration.

August 24, 2006
GE Healthcare and Volcano Corporation Announce FDA Clearance of Fully-Integrated Intravascular Ultrasound Imaging on the Innova Platform
(source: GE Healthcare and Volcano Corporation)
The FDA has given clearance to a new integrated state-of-the-art intravascular ultrasound (IVUS) platform with an all-digital X-ray cath lab imaging system. (Read more...)

August 30, 2006
Abbott Announces Completion of Enrollment in Groundbreaking Vulnerable Plaque Study
Utilizing the Volcano Therapeutics' intravascular ultrasound imaging system, the PROSPECT study, headed by Dr. Gregg Stone of Columbia University Medical Center in New York, will attempt to more clearly define who is at risk for a heart attack by looking at vulnerable plaque, not just plaque "build-up". (Read more...)